Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab

American Journal of Ophthalmology

Volumn 156, Issue 1, 2013, Pages

  Bakall, Benjamin ^a   Folk, James C ^a   Boldt, H Culver ^a   Sohn, Elliott H ^a   Stone, Edwin M ^a   Russell, Stephen R ^a   Mahajan, Vinit B ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84879235232     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.02.017     Document Type: Article

References (18)

1. D.M. Brown, P.K. Kaiser, and M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444
2. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
3. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group D.F. Martin, and M.G. Maguire Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 7 2012 1388 1398
4. J.C. Folk, and E.M. Stone Ranibizumab therapy for neovascular age-related macular degeneration N Engl J Med 363 17 2010 1648 1655
5. P.A. Keane, S. Liakopoulos, and S.C. Ongchin Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration Invest Ophthalmol Vis Sci 49 7 2008 3115 3120
6. F. Forooghian, C. Cukras, C.B. Meyerle, E.Y. Chew, and W.T. Wong Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration Retina 29 6 2009 723 731
7. S. Schaal, H.J. Kaplan, and T.H. Tezel Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115 12 2008 2199 2205
8. S. Binder Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 96 1 2012 1 2
9. J.L. Gasperini, A.A. Fawzi, and A. Khondkaryan Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation Br J Ophthalmol 96 1 2012 14 20
10. S.M. Brown, A.M. Khanani, and D.L. McCartney The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter Am J Ophthalmol 138 1 2004 149 151
11. M. Svenson, P. Geborek, T. Saxne, and K. Bendtzen Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies Rheumatology (Oxford) 46 12 2007 1828 1834
12. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 17 2002 11393 11398
13. M.W. Stewart, and P.J. Rosenfeld Predicted biological activity of intravitreal VEGF Trap Br J Ophthalmol 92 5 2008 667 668
14. M.W. Stewart Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept Clin Ophthalmol 6 2012 1175 1186
15. J.S. Heier, D.M. Brown, and V. Chong Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 12 2012 2537 2548
16. A.B. Roller, J.C. Folk, and N.M. Patel Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia Retina 31 9 2011 1848 1855
17. E. Smretschnig, I. Krebs, S. Moussa, S. Ansari-Shahrezaei, and S. Binder Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment Graefes Arch Clin Exp Ophthalmol 248 12 2010 1693 1698
18. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 9 2003 1287 1295